


PHARMACEUTICAL 2022

Entrada Therapeutics Inc. Rank 79 of 475





PHARMACEUTICAL 2022



Entrada Therapeutics Inc. Rank 79 of 475

The relative strengths and weaknesses of Entrada Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entrada Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 218% points. The greatest weakness of Entrada Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 77%, being 354% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	298,700
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,719
Liabilities, Non-Current	0
Other Assets	872
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	396
Other Net Income	-31
Property and Equipment	6,261
Research and Development	35,926
Revenues	0
Selling, General and Administrative Expense	15,201

Output Variable	Value in 1000 USD
Assets	305,833
Liabilities	7,115
Expenses	51,127
Stockholders Equity	298,718
Net Income	-51,158
Comprehensive Net Income	-51,158
Economic Capital Ratio	77%